Galapagos Advances Cell Therapy and Financial Growth
Company Announcements

Galapagos Advances Cell Therapy and Financial Growth

Galapagos (GB:0JXZ) has released an update.

Galapagos reports significant progress in its cell therapy and small molecule pipeline, with the FDA approval for its ATALANTA-1 study marking a key milestone. The company is focused on accelerating its innovation strategy to address unmet patient needs, backed by a robust financial position with €3.3 billion in cash and investments. Galapagos plans to continue expanding its clinical pipeline and decentralized manufacturing network to support ongoing and future studies.

For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyGalapagos:1st nine months FY24 net income EUR 103.5 vs. EUR 90.3 last year
TheFlyGalapagos price target lowered to EUR 29 from EUR 34 at JPMorgan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App